Hallucinations in Neurodegenerative Diseases

CNS Neuroscience and Therapeutics

Volumn 18, Issue 2, 2012, Pages 149-159

  Burghaus, Lothar ^a   Eggers, Carsten ^a   Timmermann, Lars ^a   Fink, Gereon R ^a,b   Diederich, Nico J ^c  

^a UNIVERSITY OF COLOGNE   (Germany)

^b FORSCHUNGSZENTRUM JÜLICH   (Germany)

^c CENTRE HOSPITALIER DE LUXEMBOURG   (Luxembourg)

Author keywords

Alzheimer's disease; Corticobasal degeneration; Dementia with Lewy bodies; Frontotemporal dementia; Hallucinations; Multiple system atrophy; Neurodegenerative diseases; Parkinson's disease; Progressive supranuclear palsy; Synucleinopathy; Tauopathy

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; TRAZODONE;

AGITATION; AGRANULOCYTOSIS; ALERTNESS; ALZHEIMER DISEASE; AUDITORY HALLUCINATION; COGNITIVE DEFECT; CONFUSION; COPING BEHAVIOR; CORPUS STRIATUM; CORTICOBASAL DEGENERATION; DEGENERATIVE DISEASE; DELUSION; DEPTH PERCEPTION; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; DRY SKIN; EVENING DOSAGE; FRONTOTEMPORAL DEMENTIA; HALLUCINATION; HUMAN; HYPERSALIVATION; LIMBIC CORTEX; MINI MENTAL STATE EXAMINATION; MORNING DOSAGE; MOTOR DYSFUNCTION; MYDRIASIS; NEUROPATHOLOGY; NONHUMAN; OLFACTORY HALLUCINATION; ORTHOSTATIC HYPOTENSION; PARANOIA; PARASOMNIA; PARKINSON DISEASE; PATHOGENESIS; PROGRESSIVE SUPRANUCLEAR PALSY; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; REVIEW; SEIZURE; SIDE EFFECT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP QUALITY; URINE RETENTION; VISUAL ACUITY; VISUAL CORTEX; VISUAL HALLUCINATION;

ADAPTATION, PSYCHOLOGICAL; ANIMALS; HALLUCINATIONS; HUMANS; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; SLEEP DISORDERS;

EID: 84856788716     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2011.00247.x     Document Type: Review

References (148)

1. Diederich NJ, Fenelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol 2009;5:331-342.
2. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: A retrospective autopsy study. Lancet Neurol 2005;4:605-610.
3. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391-403.
4. Galvin JE, Lee VM, Trojanowski JQ. Synucleinopathies: Clinical and pathological implications. Arch Neurol 2001;58:186-190.
5. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
6. Tu PH, Galvin JE, Baba M, et al. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein. Ann Neurol 1998;44:415-422.
7. Crowther T, Goedert M, Wischik CM. The repeat region of microtubule-associated protein tau forms part of the core of the paired helical filament of Alzheimer's disease. Ann Med 1989;21:127-132.
8. Delacourte A, Buee L. Tau pathology: A marker of neurodegenerative disorders. Curr Opin Neurol 2000;13:371-376.
9. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: Prevalence, phenomenology and risk factors. Brain 2000;123(Pt 4):733-745.
10. Goetz CG. Hallucinations in Parkinson's disease: The clinical syndrome. Adv Neurol 1999;80:419-423.
11. Ravina B, Marder K, Fernandez HH, et al. Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group. Mov Disord 2007;22:1061-1068.
12. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001;70:734-738.
13. Barnes J, David AS. Visual hallucinations in Parkinson's disease: A review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001;70:727-733.
14. Graham JM, Grunewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:434-440.
15. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:533-535.
16. Fenelon G, Thobois S, Bonnet AM, Broussolle E, Tison F. Tactile hallucinations in Parkinson's disease. J Neurol 2002;249:1699-1703.
17. Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH. Drug-induced psychosis in Parkinson disease: Phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2005;28:215-219.
18. Goetz CG, Wuu J, Curgian L, Leurgans S. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord 2006;21:267-270.
19. Marsh L, Williams JR, Rocco M, Grill S, Munro C, Dawson TM. Psychiatric comorbidities in patients with Parkinson disease and psychosis. Neurology 2004;63:293-300.
20. Hc H-D. Hallucinations in Parkinson's disease: Characteristics and associated features. Int J Geriatr Psych 1995;10:487-495.
21. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: A population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.
22. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
23. Pagonabarraga J, Llebaria G, Soriano-Mas C, et al. Gray matter changes associated with early hallucinations in Parkinson's disease. Neurology 2010;A:74-75.
24. Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Mov Disord 2008;23:2129-2170.
25. Moskovitz C, Moses H, 3rd, Klawans HL. Levodopa-induced psychosis: A kindling phenomenon. Am J Psychiatry 1978;135:669-675.
26. Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, Nora MV, Carvey PM. Intravenous levodopa in hallucinating Parkinson's disease patients: High-dose challenge does not precipitate hallucinations. Neurology 1998;50:515-517.
27. Perry EK, Perry RH. Acetylcholine and hallucinations: Disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995;28:240-258.
28. Onofrj M, Bonanni L, Albani G, Mauro A, Bulla D, Thomas A. Visual hallucinations in Parkinson's disease: Clues to separate origins. J Neurol Sci 2006;248:143-150.
29. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998;21:289-295.
30. Meppelink AM, Koerts J, Borg M, Leenders KL, van Laar T. Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. Mov Disord 2008;23:1906-1912.
31. Barnes J, Boubert L, Harris J, Lee A, David AS. Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia 2003;41:565-574.
32. de Maindreville AD, Fenelon G, Mahieux F. Hallucinations in Parkinson's disease: A follow-up study. Mov Disord 2005;20:212-217.
33. Teunisse RJ, Cruysberg JR, Hoefnagels WH, Verbeek AL, Zitman FG. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet 1996;347:794-797.
34. Ramirez-Ruiz B, Junque C, Marti MJ, Valldeoriola F, Tolosa E. Neuropsychological deficits in Parkinson's disease patients with visual hallucinations. Mov Disord 2006;21:1483-1487.
35. Goetz CG, Wuu J, Curgian LM, Leurgans S. Hallucinations and sleep disorders in PD: Six-year prospective longitudinal study. Neurology 2005;64:81-86.
36. Manni R, Terzaghi M, Repetto A. The FLEP scale in diagnosing nocturnal frontal lobe epilepsy, NREM and REM parasomnias: Data from a tertiary sleep and epilepsy unit. Epilepsia 2008;49:1581-1585.
37. Terzaghi M, Sinforiani E, Zucchella C, Zambrelli E, Pasotti C, Rustioni V, Manni R. Cognitive performance in REM sleep behaviour disorder: A possible early marker of neurodegenerative disease? Sleep Med 2008;9:343-351.
38. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment-induced hallucinations. Ann Neurol 1993;34:710-714.
39. Nomura T, Inoue Y, Mitani H, Kawahara R, Miyake M, Nakashima K. Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease. Mov Disord 2003;18:812-817.
40. Manni R, Pacchetti C, Terzaghi M, Sartori I, Mancini F, Nappi G. Hallucinations and sleep-wake cycle in PD: A 24-hour continuous polysomnographic study. Neurology 2002;59:1979-1981.
41. Dzirasa K, Ribeiro S, Costa R, et al. Dopaminergic control of sleep-wake states. J Neurosci 2006;26:10577-10589.
42. Whitehead DL, Davies AD, Playfer JR, Turnbull CJ. Circadian rest-activity rhythm is altered in Parkinson's disease patients with hallucinations. Mov Disord 2008;23:1137-1145.
43. Ramirez-Ruiz B, Marti MJ, Tolosa E, Gimenez M, Bargallo N, Valldeoriola F, Junque C. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol 2007;14:750-756.
44. Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 2005;65:1708-1715.
45. Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord 2008;23:1541-1545.
46. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-763.
47. Kalaitzakis ME, Christian LM, Moran LB, Graeber MB, Pearce RK, Gentleman SM. Dementia and visual hallucinations associated with limbic pathology in Parkinson's disease. Parkinsonism Relat Disord 2009;15:196-204.
48. Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Ann Neurol 2000;48:868-876.
49. Fox SH, Visanji N, Reyes G, Huot P, Gomez-Ramirez J, Johnston T, Brotchie JM. Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease. Can J Neurol Sci 2010;37:86-95.
50. Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Arch Neurol 2006;63:1343-1344.
51. Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov Disord 2006;21:1879-1891.
52. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson's disease. Mov Disord 2003;18:831-832.
53. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-963.
54. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: A double-blind labeled study of 3 months' duration. Mov Disord 2007;22:313-318.
55. Emre M, Cummings JL, Lane RM. Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: Similarities and differences. J Alzheimers Dis 2007;11:509-519.
56. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002;23:41-43.
57. Edwards K, Royall D, Hershey L, et al. Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 24-week open-label study. Dement Geriatr Cogn Disord 2007;23:401-405.
58. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006;21:1899-1907.
59. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age Ageing 2005;34:561-566.
60. Jellinger KA. The frequency of Lewy bodies in a consecutive autopsy series. Clin Neuropathol 1999;18:214-215.
61. McKeith IG, Dickson DW, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium. Neurology 2005;65:1863-1872.
62. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001;16:528-536.
63. Ballard C, McKeith I, Harrison R, et al. A detailed phenomenological comparison of complex visual hallucinations in dementia with Lewy bodies and Alzheimer's disease. Int Psychogeriatr 1997;9:381-388.
64. Mosimann UP, Mather G, Wesnes KA, O'Brien JT, Burn DJ, McKeith IG. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology 2004;63:2091-2096.
65. Klein JC, Eggers C, Kalbe E, et al. Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010;74:885-892.
66. Clark CM, Sheppard L, Fillenbaum GG, et al. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer disease: A clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's disease. Arch Neurol 1999;56:857-862.
67. Pagonabarraga J, Llebaria G, Garcia-Sanchez C, Pascual-Sedano B, Gironell A, Kulisevsky J. A prospective study of delusional misidentification syndromes in Parkinson's disease with dementia. Mov Disord 2008;23:443-448.
68. Perry EK, McKeith I, Thompson P, et al. Topography, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson's disease, and Alzheimer's disease. Ann N Y Acad Sci 1991;640:197-202.
69. Harding AJ, Lakay B, Halliday GM. Selective hippocampal neuron loss in dementia with Lewy bodies. Ann Neurol 2002;51:125-128.
70. Minger SL, Esiri MM, McDonald B, Keene J, Carter J, Hope T, Francis PT. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 2000;55:1460-1467.
71. Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S. The anatomy of conscious vision: An fMRI study of visual hallucinations. Nat Neurosci 1998;1:738-742.
72. Howard R, David A, Woodruff P, et al. Seeing visual hallucinations with functional magnetic resonance imaging. Dement Geriatr Cogn Disord 1997;8:73-77.
73. Mori E, Shimomura T, Fujimori M, et al. Visuoperceptual impairment in dementia with Lewy bodies. Arch Neurol 2000;57:489-493.
74. Omerovic M, Teipel SJ, Hampel T. Dementia with Lewy bodies. Clinical improvement under treatment with an acetylcholinesterase inhibitor. Nervenarzt 2007;78:1052-1057.
75. Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2005;76:1200-1203.
76. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992;305:673-678.
77. Burke WJ, Pfeiffer RF, McComb RD. Neuroleptic sensitivity to clozapine in dementia with Lewy bodies. J Neuropsychiatry Clin Neurosci 1998;10:227-229.
78. Fernandez HH, Wu CK, Ott BR. Pharmacotherapy of dementia with Lewy bodies. Expert Opin Pharmacother 2003;4:2027-2037.
79. McKeith IG, Wesnes KA, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with lewy bodies. Dement Geriatr Cogn Disord 2004;18:94-100.
80. Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, Perry RH. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 1990;55:1454-1456.
81. Shiozaki K, Iseki E, Uchiyama H, et al. Alterations of muscarinic acetylcholine receptor subtypes in diffuse lewy body disease: Relation to Alzheimer's disease. J Neurol Neurosurg Psychiatry 1999;67:209-213.
82. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
83. Bassiony MM, Lyketsos CG. Delusions and hallucinations in Alzheimer's disease: Review of the brain decade. Psychosomatics 2003;44:388-401.
84. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000;54:1965-1971.
85. Lyketsos CG, Sheppard JM, Steinberg M, Tschanz JA, Norton MC, Steffens DC, Breitner JC. Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: The Cache County study. Int J Geriatr Psychiatry 2001;16:1043-1053.
86. Steinberg M, Sheppard JM, Tschanz JT, Norton MC, Steffens DC, Breitner JC, Lyketsos CG. The incidence of mental and behavioral disturbances in dementia: The cache county study. J Neuropsychiatry Clin Neurosci 2003;15:340-345.
87. Folstein MF, Bylsma FW. Noncognitive symptoms of Alzheimer's disease. In: Ed KR, Terry RD, Bick KL, Sisodia SS, editors. Alzheimer's disease. New York: Raven Press, 1994;27-40.
88. Deutsch LH, Bylsma FW, Rovner BW, Steele C, Folstein MF. Psychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry 1991;148:1159-1163.
89. Gormley N, Rizwan MR, Lovestone S. Clinical predictors of aggressive behaviour in Alzheimer's disease. Int J Geriatr Psychiatry 1998;13:109-115.
90. Bassiony MM, Steinberg MS, Warren A, Rosenblatt A, Baker AS, Lyketsos CG. Delusions and hallucinations in Alzheimer's disease: Prevalence and clinical correlates. Int J Geriatr Psychiatry 2000;15:99-107.
91. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on memory in aging. Am J Psychiatry 2000;157:708-714.
92. Flynn FG, Cummings JL, Gornbein J. Delusions in dementia syndromes: Investigation of behavioral and neuropsychological correlates. J Neuropsychiatry Clin Neurosci 1991;3:364-370.
93. Kotrla KJ, Chacko RC, Harper RG, Doody R. Clinical variables associated with psychosis in Alzheimer's disease. Am J Psychiatry 1995;152:1377-1379.
94. Scarmeas N, Brandt J, Albert M, et al. Delusions and hallucinations are associated with worse outcome in Alzheimer disease. Arch Neurol 2005;62:1601-1608.
95. Haupt M, Kurz A. Predictors of nursing home placement in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2004;8:741-746.
96. Drevets WC, Rubin EH. Psychotic symptoms and the longitudinal course of senile dementia of the Alzheimer type. Biol Psychiatry 1989;25:39-48.
97. Rosen J, Zubenko GS. Emergence of psychosis and depression in the longitudinal evaluation of Alzheimer's disease. Biol Psychiatry 1991;29:224-232.
98. Devanand DP, Miller L, Richards M, Marder K, Bell K, Mayeux R, Stern Y. The Columbia University Scale for Psychopathology in Alzheimer's disease. Arch Neurol 1992;49:371-376.
99. Tariot PN, Mack JL, Patterson MB, et al. The Behavior Rating Scale for Dementia of the Consortium to Establish a Registry for Alzheimer's disease. The Behavioral Pathology Committee of the Consortium to Establish a Registry for Alzheimer's disease. Am J Psychiatry 1995;152:1349-1357.
100. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimer's disease: Prospective analyses from the Predictors Study. Neurology 1994;44:2300-2307.
101. Sultzer DL, Mahler ME, Mandelkern MA, Cummings JL, Van Gorp WG, Hinkin CH, Berisford MA. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1995;7:476-484.
102. Mega MS, Lee L, Dinov ID, Mishkin F, Toga AW, Cummings JL. Cerebral correlates of psychotic symptoms in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2000;69:167-171.
103. Haupt M, Janner M, Ebeling S, Stierstorfer A, Kretschmar C. Presentation and stability of noncognitive symptom patterns in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:323-329.
104. JL C. Psychosis in neurologic disease. Neuropsychiatry Neuropsychol Behav Neurol 1992;5:144-150.
105. Farber NB, Rubin EH, Newcomer JW, et al. Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry 2000;57:1165-1173.
106. Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, Chen CP, Francis PT, Lasheras B, Ramirez MJ. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. Neuropsychologia 2005;43:442-449.
107. Marcos B, Garcia-Alloza M, Gil-Bea FJ, et al. Involvement of an altered 5-HT -{6} receptor function in behavioral symptoms of Alzheimer's disease. J Alzheimers Dis 2008;14:43-50.
108. Holmes C, Smith H, Ganderton R, Arranz M, Collier D, Powell J, Lovestone S. Psychosis and aggression in Alzheimer's disease: The effect of dopamine receptor gene variation. J Neurol Neurosurg Psychiatry 2001;71:777-779.
109. Sweet RA, Nimgaonkar VL, Kamboh MI, Lopez OL, Zhang F, DeKosky ST. Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. Arch Neurol 1998;55:1335-1340.
110. US Food and Drug Administration. FDA public advisory: Controlled trial of risperidone for the treatment of aggression, deaths with antipsychotics in elderly patients with behavioral disturbances. Available from:.
111. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence. JAMA 2005;293:596-608.
112. Tariot PN, Schneider L, Katz IR, Mintzer JE, Street J, Copenhaver M, Williams-Hughes C. Quetiapine treatment of psychosis associated with dementia: A double-blind, randomized, placebo-controlled clinical trial. Am J Geriatr Psychiatry 2006;14:767-776.
113. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-1538.
114. Angelucci F, Bernardini S, Gravina P, et al. Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: A 3-year follow-up longitudinal study. J Alzheimers Dis 2009;17:203-211.
115. Wynn ZJ, Cummings JL. Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease. Dement Geriatr Cogn Disord 2004;17:100-108.
116. Larner AJ. Delusion of pregnancy in frontotemporal lobar degeneration with motor neurone disease (FTLD/MND). Behav Neurol 2008;19:199-200.
117. Mendez MF, Shapira JS, Woods RJ, Licht EA, Saul RE. Psychotic symptoms in frontotemporal dementia: Prevalence and review. Dement Geriatr Cogn Disord 2008;25:206-211.
118. Hirono N, Mori E, Tanimukai S, Kazui H, Hashimoto M, Hanihara T, Imamura T. Distinctive neurobehavioral features among neurodegenerative dementias. J Neuropsychiatry Clin Neurosci 1999;11:498-503.
119. Hodges JR, Davies RR, Xuereb JH, et al. Clinicopathological correlates in frontotemporal dementia. Ann Neurol 2004;56:399-406.
120. Tartaglia MC, Kertesz A, Ang LC. Delusions and hallucinations in frontotemporal dementia: A clinicopathologic case report. Cogn Behav Neurol 2008;21:107-110.
121. Sparks DL, Markesbery WR. Altered serotonergic and cholinergic synaptic markers in Pick's disease. Arch Neurol 1991;48:796-799.
122. Sparks DL, Danner FW, Davis DG, Hackney C, Landers T, Coyne CM. Neurochemical and histopathologic alterations characteristic of Pick's disease in a non-demented individual. J Neuropathol Exp Neurol 1994;53:37-42.
123. Procter AW, Qurne M, Francis PT. Neurochemical features of frontotemporal dementia. Dement Geriatr Cogn Disord 1999;10 (Suppl 1):80-84.
124. Engelborghs S, Vloeberghs E, Maertens K, Marescau B, De Deyn PP. Evidence for an association between the CSF HVA: 5-HIAA ratio and aggressiveness in frontotemporal dementia but not in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1080.
125. Asberg M. Neurotransmitters and suicidal behavior. The evidence from cerebrospinal fluid studies. Ann N Y Acad Sci 1997;836:158-181.
126. Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: Treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997;58:212-216.
127. Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: Paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur Neurol 2003;49:13-19.
128. Deakin JB, Rahman S, Nestor PJ, Hodges JR, Sahakian BJ. Paroxetine does not improve symptoms and impairs cognition in frontotemporal dementia: A double-blind randomized controlled trial. Psychopharmacology (Berl) 2004;172:400-408.
129. Lebert F, Stekke W, Hasenbroekx C, Pasquier F. Frontotemporal dementia: A randomised, controlled trial with trazodone. Dement Geriatr Cogn Disord 2004;17:355-359.
130. Huey ED, Putnam KT, Grafman J. A systematic review of neurotransmitter deficits and treatments in frontotemporal dementia. Neurology 2006;66:17-22.
131. Chow TW, Mendez MF. Goals in symptomatic pharmacologic management of frontotemporal lobar degeneration. Am J Alzheimers Dis Other Demen 2002;17:267-272.
132. Moretti R, Torre P, Antonello RM, Cazzato G, Griggio S, Bava A. Olanzapine as a treatment of neuropsychiatric disorders of Alzheimer's disease and other dementias: A 24-month follow-up of 68 patients. Am J Alzheimers Dis Other Demen 2003;18:205-214.
133. Curtis RC, Resch DS. Case of pick's central lobar atrophy with apparent stabilization of cognitive decline after treatment with risperidone. J Clin Psychopharmacol 2000;20:384-385.
134. Fellgiebel A, Muller MJ, Hiemke C, Bartenstein P, Schreckenberger M. Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. World J Biol Psychiatry 2007;8:123-126.
135. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology 1996;47:1-9.
136. Diederich NJ, Leurgans S, Fan W, Chmura TA, Goetz CG. Visual hallucinations and symptoms of REM sleep behavior disorder in Parkinsonian tauopathies. Int J Geriatr Psychiatry 2008;23:598-603.
137. Cooper AD, Josephs KA. Photophobia, visual hallucinations, and REM sleep behavior disorder in progressive supranuclear palsy and corticobasal degeneration: A prospective study. Parkinsonism Relat Disord 2009;15:59-61.
138. Geda YE, Boeve BF, Negash S, et al. Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. J Neuropsychiatry Clin Neurosci 2007;19:77-80.
139. Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:42-49.
140. Kompoliti K, Goetz CG, Litvan I, Jellinger K, Verny M. Pharmacological therapy in progressive supranuclear palsy. Arch Neurol 1998;55:1099-1102.
141. Litvan I, Cummings JL, Mega M. Neuropsychiatric features of corticobasal degeneration. J Neurol Neurosurg Psychiatry 1998;65:717-721.
142. Litvan I, Mega MS, Cummings JL, Fairbanks L. Neuropsychiatric aspects of progressive supranuclear palsy. Neurology 1996;47:1184-1189.
143. Menza MA, Cocchiola J, Golbe LI. Psychiatric symptoms in progressive supranuclear palsy. Psychosomatics 1995;36:550-554.
144. Stefanova N, Bucke P, Duerr S, Wenning GK. Multiple system atrophy: An update. Lancet Neurol 2009;8:1172-1178.
145. Malone D, Dennis MS. Multiple system atrophy and hallucinations-a short report. Int J Geriatr Psychiatry 2005;20:699-700.
146. Papapetropoulos S, Tuchman A, Laufer D, Mash DC. Hallucinations in multiple system atrophy. Parkinsonism Relat Disord 2007;13:193-194.
147. Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 1999;163:94-98.
148. Litvan I, Goetz CG, Jankovic J, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol 1997;54:937-944.